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various intestinal and extraintestinal diseases. It is a known fact that the
digestive tract may serve as a portal of entry into the bloodstream.
Therefore, the presence of highly resistant E. coli strains in the gut presents
a threat to the patients with predispositions such as chronic illnesses and
poor immune status.
Methods: This study was undertaken with the aim to determine the
resistance pattern among the E. coli strains isolated from the gut of
chronically ill patients across wide clinical settings. The study was conducted
over a period of 1 year from 1 January 2011 to 31 December 2011. Stool
samples from patients admitted for more than 14 days in wards of all major
clinical specialities were collected after proper counselling and informed
consent. E. coli were identified on the basis of cultural characteristics and
biochemical reactions. Strains isolated from pediatric patients were
subjected to serotyping by the slide agglutination test with specific antisera
(Denka Seiken Co., Ltd, Tokyo, Japan) to identify the enterovirulent strains.
All E. coli strains were subjected to antimicrobial susceptibility testing and
ESBL identification by the disk diffusion methods in accordance with the
CLSI guidelines.
Results: Two hundred and fifty-four patients were included in the study with
the following distribution: 71 from a pediatrics ward, 62 from a general
medicine ward, 54 from a general surgery ward, 42 from a gynaecology ward,
16 from an orthopaedics ward and nine from an ENT ward. E. coli was isolated
from 112 samples. Out of 34 E. coli strains isolated from paediatric patients, 14
were determined to be enterovirulent E. coli by serotyping. Antimicrobial
susceptibility testing of all E. coli strains showed 100% resistance to nalidixic
acid and a high degree of resistance to ampicillin (87.5%), doxycyline
(83.0%), cotrimoxazole (75.9%), ciprofloxacin (73.2%) and third-generation
cephalosporins (71.4%). ESBL production was detected in 71 strains (63.4%).
However, no resistance was found for carbapenems and tigecycline.
Conclusion: A large population of chronically ill patients who were tested
was found to be carrying highly resistant E. coli in their guts. These usually
commensal strains may serve as a source of bloodstream infection especially
in cases of immunosuppression. Whether these strains were acquired in the
hospital or from the community needs to be studied further.
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Background: One hallmark contributing to immune suppression during the
l a t ep h a s eo fs e p s i si sm a c r o p h a g ep o l arization to an anti-inflammatory
phenotype upon contact with apoptotic cells (AC). Taking the important role
of the nuclear receptor PPARg for this phenotype switch into consideration,
it remains elusive how AC activate PPARg in macrophages. Therefore, we
were interested to characterize the underlying principle.
Methods: Apoptosis was induced by treatment of Jurkat T cells for
3 hours with 0.5 μg/ml staurosporine. Necrotic cells (NC) were prepared
by heating cells for 20 minutes to 65°C. PPARg activation was followed by
stably transducing RAW264.7 macrophages with a vector encoding the
red fluorescent protein mRuby after PPARg binding to 4 × PPRE sites
downstream of the reporter gene sequence. This readout was established
by treatment with the PPARg agonist rosiglitazone (1 μM) and AC (5:1).
Twenty-four hours after stimulation, mRuby expression was analysed by
fluorescence microscopy. Lipid rafts of AC, NC, as well as living cells (LC)
were enriched by sucrose gradient centrifugation. Fractions were
analysed for lipid raft-associated marker proteins. Lipid rafts were
incubated with transduced RAW264.7 macrophages as described above.
5-Lipoxygenase (5-LO) involvement was verified by pharmacological
inhibition (MK-866, 1 μM) and overexpression.
Results: Assuming that the molecule responsible for PPARg activation in
macrophages is localized in the cell membrane of AC, most probably
associated to lipid rafts, we isolated lipid rafts from AC, NC and LC. Mass
spectrometric analysis of lipid rafts of AC showed the expression of 5-LO,
whereas lipid rafts of LC did not. Moreover, incubating macrophages with
lipid rafts of AC induced mRuby expression. In contrast, lipid rafts of NC and
LC did not. To verify the involvement of 5-LO in activating PPARg in
macrophages, Jurkat T cells were incubated for 30 minutes with the 5-LO
inhibitor MK-866 (1 μM) before apoptosis induction. In line with our
hypothesis, these AC did not induce mRuby expression. Finally, although
living Jurkat T cells overexpressing 5-LO did not activate PPARg in
macrophages, mRuby expression was significantly increased when AC were
generated from 5-LO overexpressing compared with wild-type Jurkat cells.
Conclusion: Our results suggest that induction of apoptosis activates 5-LO,
localizing to lipid rafts, necessary for PPARg activation in macrophages.
Therefore, it will be challenging to determine whether 5-LO activity in AC,
generated from other cell types, correlates with PPARg activation,
contributing to an immune-suppressed phenotype in macrophages.
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Background: As sensors of infection, innate immune cells are able to
recognize pathogen-associated molecular patterns by receptors such as Toll-
like receptors (TLRs). Natural killer (NK) cells contribute to inflammatory
processes by producing proinflammatory cytokines such as IFNg and GM-
CSF [1]. Our aim was to characterize the immune status of NK cells in a
murine model of sepsis and in patients with systemic inflammatory
response syndrome (SIRS) and sepsis.
Methods: Cecal puncture (CP) was employed as a murine model of
polymicrobial sepsis. TLR expression in murine and human NK cells was
studied by flow cytometry. Ex vivo IFNg production was analyzed either by
ELISA or by flow cytometry.
Results: In mice, the expression of TLR2 and TLR4 in spleen NK cells is
mainly intracellular, similarly to TLR9. In vitro cell responsiveness of purified
NK cells to TLR2, TLR4 or TLR9 agonists, in synergy with accessory cytokines
(IL-2, IL-15 and IL-18), allowed a significant production of IFNg and GM-CSF.
In contrast, NK cells, purified from spleen of mice with sepsis, showed a
dramatic reduction of their capacity to produce cytokines in response to TLR
agonists. Depletion of regulatory T cells (Tregs) before CP led to a complete
reversion of NK cell tolerance to TLR agonists. IL-10 and TGF-b1a r et w o
main inhibitory cytokines produced by Tregs. We showed in vivo, using IL-10
knockout mice and by inhibiting TGF-bR signaling, that the tolerization
mechanism of NK cells was mostly mediated by TGF-b [2]. In humans, the
expression of TLR2, TLR4 and TLR9 in peripheral blood NK cells (both CD3
-
CD56
high and CD3
-CD56
dim subsets) was mainly intracellular. The ex vivo
responsiveness of the blood NK cells to their agonists in synergy with
accessory cytokines (IL-15 and IL-18), allowed a significant secretion of IFNg.
Similar to the murine model of sepsis, in SIRS and sepsis patients the
secretion of IFNg by NK cells was significantly decreased.
Conclusion: NK cells express TLR2 and TLR4 intracellularly, as already
reported for other cell types (epithelial, endothelial, and dendritic cells).
Furthermore, NK cells undergo tolerance to TLR agonists during SIRS or
sepsis, as already described for monocytes in these clinical settings.
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